NCT01378130

Brief Summary

Pathogenesis of central serous chorioretinopathy is not entirely understood yet, therefore further investigations are needed. During this study patients with an acute episode of central serous chorioretinopathy are observed with established ophthalmologic methods (multimodal imagine) every 6 weeks until subretinal fluid is reabsorbed to gain further insides in etiology, course and prognosis of this disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 20, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 22, 2011

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
Last Updated

April 26, 2013

Status Verified

April 1, 2013

Enrollment Period

2 years

First QC Date

June 20, 2011

Last Update Submit

April 25, 2013

Conditions

Central Serous Chorioretinopathy

Keywords

CCSCSCSubretinal Fluidmultimodal imaging

Outcome Measures

Primary Outcomes (1)

  • Clinical Outcome

    OCT, Visus

    2 years

Secondary Outcomes (1)

  • Subclinical Data

    2 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with an acute episode of central serous chorioretinopathy are recruited from the Department of Ophthalmology at the Medical University of Vienna.

You may qualify if:

  • Signed informed consent form
  • Age over 18 years
  • acute episode of Central Serous Chorioretinopathy
  • Symptoms for less than two weeks
  • no treatment on study eye

You may not qualify if:

  • bad compliance
  • protected patient group (pregnant women)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vienna Gerenal Hospital

Vienna, Austria

Location

MeSH Terms

Conditions

Central Serous Chorioretinopathy

Condition Hierarchy (Ancestors)

Retinal DiseasesEye Diseases

Study Officials

  • Stefan Sacu, Ass.Prof.Dr.

    Department of Ophthalmology, Medical University of Vienna, Austria

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prof. Dr.

Study Record Dates

First Submitted

June 20, 2011

First Posted

June 22, 2011

Study Start

April 1, 2011

Primary Completion

April 1, 2013

Study Completion

April 1, 2013

Last Updated

April 26, 2013

Record last verified: 2013-04

Locations

AU(1)